- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03598712
Local Compression Seroma DIminution Objective (CLODIS) (CLODIS)
Interest of Local Compression by Thoracic Bandage on the Management of Seroma in Patients Treated by Mastectomy With or Without Lymphadenectomy. Local Compression Seroma DIminution Objective
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: JULIE TANQUREL, NURSE
- Phone Number: 33231455631
- Email: j.tanquerel@baclesse.unicancer.fr
Study Contact Backup
- Name: FRANCOIS GERNIER, PROJECT MANAGER
- Phone Number: 33231454043
- Email: f.gernier@baclesse.unicancer.fr
Study Locations
-
-
-
Caen, France, 14400
- Recruiting
- TANQUEREL Julie
-
Contact:
- JULIE TANQUEREL, NURSE
- Phone Number: 33 2 31 45 5631
- Email: j.tanquerel@baclesse.unicancer.fr
-
Contact:
- FRANCOIS GERNIER, PROJECT MANAGER
- Phone Number: 33 2 31 45 4043
- Email: f.gernier@baclesse.unicancer.fr
-
Principal Investigator:
- JEAN-FRANCOIS LEBRUN, MD
-
Caen, France
- Recruiting
- Centre Françis Baclesse
-
Contact:
- Jean-François LEBRUN, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient followed for histologically proven breast cancer treated by total mastectomy, whether or not dissociated from the sentinel node technique, with or without axillary curing.
- Patient with a second seroma puncture with a volume greater than or equal to 250 ml.
- Neo adjuvant chemotherapy authorized.
- Absence of known metastases.
- Patient has given written consent.
Exclusion Criteria:
- Mastectomy with immediate reconstruction.
- Partial mastectomy.
- Concurrent bilateral mastectomy.
- Delay in healing observed at inclusion.
- Patient under legal protection.
- Chronic respiratory failure.
- Patient with a pacemaker.
- Personality disorders and known progressive psychiatric pathology.
- Inability to submit to trial follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Compression by chest bandage urgo K2®
After the second puncture, the local compression by thoracic bandage will be put in place. The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out. During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit. The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation. |
Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners.
They define the indication of the puncture.
The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
|
Active Comparator: punctures
After the second puncture, the patient will be seen at the same frequency as in the experimental arm. The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical. |
Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners.
They define the indication of the puncture.
The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of puncture(s) after inclusion in both patient groups
Time Frame: 180 days
|
In each group, we will count the number of punctures performed after the 2nd puncture with a volume > 250ml (inclusion).
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time required to take charge of adjuvant treatments
Time Frame: 180 days
|
Deferral of adjuvant therapy related to seroma: Treatment regimen and adjuvant appointments will be collected at inclusion.
Each deviation will be analyzed and attributed or not to the presence or complications of seroma.
|
180 days
|
Volume punctured after inclusion in both patient groups.
Time Frame: 180 days
|
For each new puncture, the volume of serolymphatic fluid will be measured and the time between two punctures analyzed
|
180 days
|
comparison of the average change Quality of life scores between each arm
Time Frame: 180 days
|
Quality of life is assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, for the cancer in general and EORTC QLQ-BR23 specifically for the breast cancer (study inclusion and exit).
The EORTC QLQ-C30 questionnaire, resulting in a score for the quality of life between 0 to 100.
|
180 days
|
comparison of the average change anxiety scores between each arm
Time Frame: 180 days
|
Anxiety / depressions are assessed by the Hospital Anxiety and Depression scale (study inclusion and exit)
|
180 days
|
comparison of the average change Pain scores between each arm
Time Frame: 180 days
|
|
180 days
|
The aesthetic impact on the puncture site.
Time Frame: 180 days
|
The evaluation of the aesthetic impact on the puncture zone will be carried out by comparing the photographs taken at the inclusion, during the visit to the consultation at 10-15 days after the last puncture (for the standard arm) and at 10-15 days after the removal of the bandage device and finally during the consultation with the oncologist.
|
180 days
|
Validation of a score allowing the description of the seroma of grades 2 and the indication of a puncture
Time Frame: 180 days
|
Based on the observation grids carried out by the 2 professionals during a separate evaluation, we compare the 4 items defined to the indication chosen for the puncture as well as the volume of puncture when it is carried out.
|
180 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLODIS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Compression by chest bandage urgo K2®
-
Gerencia de Atención Primaria, MadridFondo de Investigacion Sanitaria; Instituto de Salud Carlos IIICompleted
-
Ankara City Hospital BilkentAnkara Training and Research HospitalCompleted
-
Ankara City Hospital BilkentAnkara Training and Research HospitalCompleted
-
Karolinska InstitutetThe Swedish Research Council; Swedish Heart Lung Foundation; SOS AlarmRecruitingCardiac Arrest | Cardiopulmonary Resuscitation | Out-Of-Hospital Cardiac ArrestSweden
-
Nantes University HospitalCompleted
-
St. Jude Children's Research HospitalAssisi FoundationCompletedLymphoma | LeukemiaUnited States